Combination chemotherapy with paclitaxel, ifoseamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy: Advanced report

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2006年 / 5卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：291 / 291
页数：1
相关论文
共 50 条
  • [31] Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
    M B Polee
    W C J Hop
    T C Kok
    F A L M Eskens
    M E L van der Burg
    T A W Splinter
    P D Siersema
    H W Tilanus
    G Stoter
    A van der Gaast
    British Journal of Cancer, 2003, 89 : 2045 - 2050
  • [32] Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
    Polee, MB
    Hop, WCJ
    Kok, TC
    Eskens, FALM
    van der Burg, MEL
    Splinter, TAW
    Siersema, PD
    Tillanus, HW
    Stoter, G
    van der Gaast, A
    BRITISH JOURNAL OF CANCER, 2003, 89 (11) : 2045 - 2050
  • [33] Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies
    Masatomo Nishikawa
    Hideaki Miyake
    Masato Fujisawa
    International Journal of Clinical Oncology, 2016, 21 : 162 - 167
  • [34] Editorial Comment to Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer
    Yuasa, Takeshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (09) : 975 - 975
  • [35] IRINOTECAN AND NEDAPLATIN AS SALVAGE THERAPY FOR PATIENTS WITH ADVANCED GERM CELL TUMOR FOLLOWING INTENSIVE TREATMENT WITH CISPLATIN-BASED COMBINATION CHEMOTHERAPIES
    Nishikawa, Masatomo
    Miyake, Hideaki
    Fujisawa, Masato
    JOURNAL OF UROLOGY, 2016, 195 (04): : E1060 - E1060
  • [36] Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies
    Nishikawa, Masatomo
    Miyake, Hideaki
    Fujisawa, Masato
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (01) : 162 - 167
  • [37] The combination chemotherapy of docetaxel, ifosfamide, and cisplatin (DIP) in patients with advanced urothelial cancer
    Takahashi, S
    Suzuki, M
    Tomita, K
    Takeuchi, T
    Ohta, N
    Kitamura, T
    JOURNAL OF UROLOGY, 2004, 171 (04): : 83 - 83
  • [38] Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
    Li, Y.
    Wang, X.
    Li, J.
    Ding, W.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2015, 36 (01) : 54 - 58
  • [39] Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy
    Patterson, Karl
    Prabhu, Vimalanand
    Xu, Ruifeng
    Li, Haojie
    Meng, Yang
    Zarabi, Natalie
    Zhong, Yichen
    Batteson, Rachael
    Pellissier, James
    Keefe, Stephen
    Grivas, Petros
    de Wit, Ronald
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (05): : 565 - 571
  • [40] Management of Spontaneous Aortic Thrombus Following Cisplatin-Based Chemotherapy in Urothelial Cancer: A Case Report
    Zheng, Victoria Meijia
    Le Linn, Yun
    Ch'ng, Jack Kian
    Chng, Siew Ping
    VASCULAR SPECIALIST INTERNATIONAL, 2023, 39
12345